Develops small-molecule anti-cancer drugs targeting the TET2 enzyme
| Date | Round | Amount |
|---|---|---|
| Nov 2022 | Series A Oslo preclinical pharma Hemispherian closed a USD2.9M first tranche of its Series A1, led by Meneldor, to advance its cancer drug pipeline. | $2.9M |
| May 2022 | Seed Oslo preclinical pharma Hemispherian raised a USD1.4M (NOK 12.5M) oversubscribed seed round led by Meneldor. | $1.4M |